Vaxchora Availability: What Providers and Prescribers Need to Know in 2026

Clinicians advising patients preparing to travel to cholera-affected areas face a recurring access challenge: Vaxchora, the only FDA-approved cholera vaccine in the United States, is frequently difficult for patients to locate. Understanding why — and having practical strategies ready — is essential for providers who want to ensure their patients depart protected.

This 2026 guide covers current availability, clinical eligibility criteria, contraindications, key drug interactions, and how to guide patients toward accessible vaccination.

Current Vaxchora Availability Status (2026)

Vaxchora is not on the FDA drug shortage list as of 2026. The vaccine is manufactured by Bavarian Nordic A/S following its acquisition from Emergent BioSolutions in May 2023. Bavarian Nordic reported significant revenue growth for Vaxchora in 2024 and has been expanding distribution in US and European markets.

The access barrier is structural, not a production shortage. Vaxchora is distributed through travel health clinic channels and vaccine wholesalers — not through standard retail pharmacy distribution networks. Chain pharmacies (CVS, Walgreens, Rite Aid) rarely carry it. Patients and providers should expect to source it through travel medicine clinics, hospital travel medicine or infectious disease departments, or specialty pharmacies.

Indications and ACIP Recommendations

FDA Approval: Vaxchora is indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in persons 2 through 64 years of age traveling to cholera-affected areas.

ACIP Recommendation: The CDC's Advisory Committee on Immunization Practices recommends Vaxchora for adult travelers ages 18–64 going to areas of active cholera transmission (defined as having cholera cases reported within the past year). ACIP updated its recommendations in September 2022 following pediatric approval.

Limitations of use to communicate to patients:

• Efficacy has not been established in persons living in cholera-endemic areas or those with pre-existing V. cholerae immunity
• Vaxchora does not protect against V. cholerae serogroup O139 or other non-O1 serogroups
• Revaccination safety and efficacy have not been established

Dosing Summary

Vaxchora is a single oral dose:

• Adults and children 6–64 years: 100 mL oral suspension
• Children 2–5 years: 50 mL oral suspension
• Timing: Administer a minimum of 10 days before potential cholera exposure
• Administration: Oral only; must be prepared and consumed in a healthcare setting; patient should fast (no food or drink) for 60 minutes before and after ingestion

Contraindications

Vaxchora is contraindicated in:

• Persons with a history of severe allergic reaction (e.g., anaphylaxis) to any ingredient of Vaxchora or to a previous dose of any cholera vaccine
• Immunocompromised persons (safety and effectiveness have not been established; use with caution given the live-attenuated nature of the vaccine)

Key Drug Interactions to Screen For

Providers should screen for these interactions before administering Vaxchora:

• Systemic antibiotics: Do not administer Vaxchora to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination. Antibiotics active against V. cholerae can suppress vaccine strain replication, preventing adequate immune response.
• Chloroquine (antimalarial): Data suggest chloroquine may diminish immune responses to Vaxchora. Administer Vaxchora at least 10 days before beginning chloroquine prophylaxis.
• Immunosuppressive therapies: Corticosteroids (above physiologic doses), antimetabolites, alkylating agents, cytotoxic drugs, and irradiation may diminish immune response. Avoid live vaccines for at least 3 months after cessation of high-dose immunosuppressives.
• Typhoid vaccine Ty21a (Vivotif): Separate administration by at least 2 hours due to the Vaxchora buffer potentially affecting Ty21a capsule transit.

Shedding and Transmission Counseling Points

Providers should counsel patients about vaccine strain shedding:

• The vaccine strain may be shed in stool for at least 7 days post-vaccination
• Potential for transmission to non-vaccinated close contacts exists; use caution in patients with immunocompromised household members
• Patients should wash hands thoroughly after using the bathroom and before handling food for at least 14 days post-vaccination

Helping Patients Access Vaxchora

When your patients can't fill a Vaxchora prescription, direct them to medfinder for providers — a service that contacts pharmacies and travel clinics on the patient's behalf to locate available stock. This reduces the burden on patients who may not know where to begin and helps ensure they can be vaccinated in time.

Additionally, if your practice has appropriate cold storage (2–8°C) and trained staff, ordering Vaxchora directly through a vaccine distributor is an option for high-volume travel medicine practices. Contact Bavarian Nordic's medical information line at (844) 422-8274 for ordering and distribution guidance.

For a detailed provider workflow, see our companion guide: How to Help Your Patients Find Vaxchora in Stock: A Provider's Guide.